<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X13481110</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X13481110</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Comparing Bayesian and Frequentist Approaches for Multiple Outcome Mixed Treatment Comparisons</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hong</surname><given-names>Hwanhee</given-names></name>
<degrees>MS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Carlin</surname><given-names>Bradley P.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Shamliyan</surname><given-names>Tatyana A.</given-names></name>
<degrees>MD, MS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Wyman</surname><given-names>Jean F.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Ramakrishnan</surname><given-names>Rema</given-names></name>
<degrees>MPH</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sainfort</surname><given-names>François</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Kane</surname><given-names>Robert L.</given-names></name>
<degrees>MD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X13481110">Division of Biostatistics (HH, BPC), University of Minnesota, Minneapolis</aff>
<aff id="aff2-0272989X13481110">Division of Health Policy and Management (TS, JFW, RR, FS, RLK), University of Minnesota, Minneapolis</aff>
<author-notes>
<corresp id="corresp1-0272989X13481110">Hwanhee Hong, Division of Biostatistics, University of Minnesota, A460 Mayo Building, MMC 303, 420 Delaware St, SE, Minneapolis, MN 55455, USA; phone: (617) 963-4132; e-mail: <email>hong0362@umn.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>5</issue>
<fpage>702</fpage>
<lpage>714</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>2</month>
<year>2013</year>
</date>
</history>
<abstract>
<p><bold>Objectives</bold>. Bayesian statistical methods are increasingly popular as a tool for meta-analysis of clinical trial data involving both direct and indirect treatment comparisons. However, appropriate selection of prior distributions for unknown model parameters and checking of consistency assumptions required for modeling remain particularly challenging. We compared Bayesian and traditional frequentist statistical methods for mixed treatment comparisons with multiple binary outcomes. <bold>Data</bold>. We searched major electronic bibliographic databases, Food and Drug Administration reviews, trial registries, and research grant databases up to December 2011 to find randomized studies published in English that examined drugs for female urgency urinary incontinence (UI) on continence, improvement in UI, and treatment discontinuation due to harm. <bold>Methods</bold>. We describe and fit fixed and random effects models in both Bayesian and frequentist statistical frameworks. In a hierarchical model of 8 treatments, we separately analyze 1 safety and 2 efficacy outcomes. We produce Bayesian and frequentist treatment ranks and odds ratios across all drug v placebo comparisons, as well as Bayesian probabilities that each drug is best overall through a weighted scoring rule that trades off efficacy and safety. <bold>Results</bold>. In our study, Bayesian and frequentist random effects models generally suggest the same drugs as most attractive, although neither suggests any significant differences between drugs. However, the Bayesian methods more consistently identify one drug (propiverine) as best overall, produce interval estimates that are generally better at capturing all sources of uncertainty in the data, and also permit attractive “rankograms” that visually capture the probability that each drug assumes each possible rank. <bold>Conclusions</bold>. Bayesian methods are more flexible and their results more clinically interpretable, but they require more careful development and specialized software.</p>
</abstract>
<kwd-group>
<kwd>nephrology</kwd>
<kwd>Bayesian meta-analysis</kwd>
<kwd>comparative effectiveness</kwd>
<kwd>systematic reviews</kwd>
<kwd>hierarchical models</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0272989X13481110" sec-type="intro">
<title>Introduction</title>
<sec id="section2-0272989X13481110">
<title>Background</title>
<p>There is growing interest in assessing the relative effects of treatments by comparing one to another.<sup><xref ref-type="bibr" rid="bibr1-0272989X13481110">1</xref><xref ref-type="bibr" rid="bibr2-0272989X13481110"/>–<xref ref-type="bibr" rid="bibr3-0272989X13481110">3</xref></sup> Because few studies are typically available to provide evidence from direct head-to-head comparisons, systematic reviews frequently rely on <italic>indirect</italic> comparisons that use statistical techniques to estimate the treatment effects from studies of each given treatment against controls under an assumption of consistency of effects across studies.<sup><xref ref-type="bibr" rid="bibr4-0272989X13481110">4</xref><xref ref-type="bibr" rid="bibr5-0272989X13481110"/><xref ref-type="bibr" rid="bibr6-0272989X13481110"/><xref ref-type="bibr" rid="bibr7-0272989X13481110"/><xref ref-type="bibr" rid="bibr8-0272989X13481110"/>–<xref ref-type="bibr" rid="bibr9-0272989X13481110">9</xref></sup> The problems with such systematic reviews, meta-analysis, and evidence synthesis are that the circumstances of each study and the samples examined may vary, and controls may also differ among studies.</p>
<p>A number of techniques have been proposed to address these challenges.<sup><xref ref-type="bibr" rid="bibr6-0272989X13481110">6</xref><xref ref-type="bibr" rid="bibr7-0272989X13481110"/><xref ref-type="bibr" rid="bibr8-0272989X13481110"/>–<xref ref-type="bibr" rid="bibr9-0272989X13481110">9</xref></sup> <italic>Mixed (or multiple) treatment comparisons</italic> (MTCs), sometimes called <italic>network meta-analysis</italic>, refers to methods that compare treatments by combining all available evidence from studies that form a network of evidence (including studies comparing 3 or more treatment arms) in the absence of sufficient direct head-to-head comparisons. Either Bayesian or frequentist approaches can be used in MTCs. By synthesizing direct and indirect comparisons, we can improve the precision of estimates for treatment effects. Although classical (or frequentist) statistical methods for MTCs certainly exist, they become increasingly difficult to fit more complex models. In contrast, a Bayesian analysis can easily construct such complicated models with lower restrictive assumptions and permits explicit posterior inference regarding drug-specific odds ratios and the probability that each treatment is “best” for a specific outcome.<sup><xref ref-type="bibr" rid="bibr10-0272989X13481110">10</xref>,<xref ref-type="bibr" rid="bibr11-0272989X13481110">11</xref></sup></p>
<p>In this article, we use an example from a recent systematic review of drugs to treat urinary incontinence in adult women<sup><xref ref-type="bibr" rid="bibr12-0272989X13481110">12</xref></sup> to compare Bayesian and frequentist approaches with respect to their ease and flexibility, the magnitudes of estimated variabilities (i.e., <italic>heterogeneity</italic>), consistency and robustness to departures from assumptions, and clinical interpretability.<sup><xref ref-type="bibr" rid="bibr13-0272989X13481110">13</xref>,<xref ref-type="bibr" rid="bibr14-0272989X13481110">14</xref></sup> We also describe more complex Bayesian hierarchical models that account for evidence <italic>inconsistency</italic>, defined as the incompatibility between direct and indirect evidence,<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref></sup> and provide tools to find the best overall treatment by using various metrics based on a sensible scoring system to combine efficacy and safety outcomes.</p>
<p>Urgency urinary incontinence (UI) is defined as involuntary loss of urine associated with the sensation of a sudden, compelling urge to void that is difficult to defer.<sup><xref ref-type="bibr" rid="bibr16-0272989X13481110">16</xref></sup> Continence (complete voluntary control of the bladder) has been considered a primary goal in UI treatment<sup><xref ref-type="bibr" rid="bibr17-0272989X13481110">17</xref>,<xref ref-type="bibr" rid="bibr18-0272989X13481110">18</xref></sup> and is the most important outcome associated with quality of life in women with UI.<sup><xref ref-type="bibr" rid="bibr19-0272989X13481110">19</xref></sup> In our original review, we used traditional frequentist meta-analysis techniques and concluded that drugs for urgency UI have comparable efficacy and that the magnitude of the benefits from such drugs is small. Details of the search strategy, inclusion criteria, and other features of the review are described elsewhere.<sup><xref ref-type="bibr" rid="bibr12-0272989X13481110">12</xref></sup> Briefly, we synthesized rates of continence, improvement in UI, and discontinuation of the treatments due to adverse events (AEs) (<xref ref-type="table" rid="table1-0272989X13481110">Table 1</xref>) of 8 drugs, including placebo, from 83 randomized controlled trials (RCTs). We used discontinuation due to AEs as our safety end point because this addressed women’s perception of the burden and seriousness of the adverse effects, as well as adherence to the treatments.</p>
<table-wrap id="table1-0272989X13481110" position="float">
<label>Table 1</label>
<caption>
<p>Definitions of 3 outcomes</p>
</caption>
<graphic alternate-form-of="table1-0272989X13481110" xlink:href="10.1177_0272989X13481110-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="center">Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continence</td>
<td>Absence of any involuntary leakage of urine</td>
</tr>
<tr>
<td/>
<td>Author’s reports of cure, absence of incontinent episodes in bladder diaries, negative pad<break/>stress, or no abnormalities noted on urodynamics</td>
</tr>
<tr>
<td>Improvement in urinary incontinence</td>
<td>Reduction frequency and severity of incontinence episodes by &gt;50%</td>
</tr>
<tr>
<td/>
<td>Reduction in pad stress test by &gt;50%</td>
</tr>
<tr>
<td/>
<td>Reduction in restrictions of daily activities due to incontinence</td>
</tr>
<tr>
<td/>
<td>Women’s perception of clinically important improvement in their bladder using various scales</td>
</tr>
<tr>
<td>Discontinuation of treatment due to adverse effect</td>
<td>Subject refusal to continue treatment due to adverse effects or physician decision to withdraw treatment due to adverse effects</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Among 83 RCTs, 65 studies were included in our original analysis. Each study reported the number of events and the sample size for drugs and outcomes investigated. <xref ref-type="fig" rid="fig1-0272989X13481110">Figure 1</xref> exhibits the network between drugs for each outcome.<sup><xref ref-type="bibr" rid="bibr20-0272989X13481110">20</xref></sup> The size of each node represents the number of studies investigating the drug, and the thickness of each edge corresponds to the total number of samples for the relation. The number on each edge is the number of studies for the relation. There are 19 studies for continence, 28 studies reporting the UI improvement outcome, and 47 studies for discontinuation. <xref ref-type="fig" rid="fig1-0272989X13481110">Figure 1(a)</xref> shows that none of the studies for the continence outcome included darifenacin as a treatment arm. <xref ref-type="fig" rid="fig1-0272989X13481110">Figure 1(c)</xref> displays a much more complex network structure for the discontinuation outcome, including several drug-to-drug (and not merely drug-to-placebo) comparisons. We provide the original data in Web Appendix 1.</p>
<fig id="fig1-0272989X13481110" position="float">
<label>Figure 1</label>
<caption>
<p>Network graphs of urinary incontinence (UI) data for each outcome: (a) continence, (b) UI improvement, and (c) discontinuation due to adverse events (AEs). The size of each node represents the number of studies investigating the drug, and the thickness of each edge implies the total number of samples for the relation. The number on the line is the number of studies for the relation.</p>
</caption>
<graphic xlink:href="10.1177_0272989X13481110-fig1.tif"/>
</fig>
</sec>
</sec>
<sec id="section3-0272989X13481110" sec-type="methods">
<title>Methods</title>
<sec id="section4-0272989X13481110">
<title>Bayesian Approach</title>
<p>Hierarchical statistical meta-analysis for MTCs with binary outcomes has a substantial history in the literature.<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref>,<xref ref-type="bibr" rid="bibr21-0272989X13481110">21</xref><xref ref-type="bibr" rid="bibr22-0272989X13481110"/>–<xref ref-type="bibr" rid="bibr23-0272989X13481110">23</xref></sup> We began by fitting 4 logit models initially proposed by Lu and Ades,<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref></sup> who suggest a fully Bayesian hierarchical approach to estimate a relative effect of 2 treatments, using a log odds ratio of the magnitude of the 2 effects in the binary case.</p>
<p>We assume that the event data from each study follow a binomial distribution. That is,</p>
<p>
<disp-formula id="disp-formula1-0272989X13481110">
<mml:math display="block" id="math1-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>B</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>I</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq1.tif"/>
</disp-formula>
</p>
<p>where <italic>r<sub>ik</sub></italic> is the total number of events, <italic>n<sub>ik</sub></italic> is the total number of subjects, and <italic>p<sub>ik</sub></italic> is the probability of the outcome in the <italic>k</italic>th treatment arm from the <italic>i</italic>th study, with <italic>k</italic> = 1 for the placebo arm. Logistic regression is commonly used to fit this type of data. The model can be written as</p>
<p>
<disp-formula id="disp-formula2-0272989X13481110">
<mml:math display="block" id="math2-0272989X13481110">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>B</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq2.tif"/>
</disp-formula>
</p>
<p>where <italic>B</italic> represents a baseline treatment (the treatment assigned the smallest <italic>k</italic> value in each study, usually placebo), µ<sub><italic>iB</italic></sub> is the effect of the baseline treatment in the <italic>i</italic>th study, and Δ<sub><italic>Bk</italic></sub> is the log odds ratio between the <italic>k</italic>th treatment and the baseline treatment. For inference, we define <italic>d<sub>k</sub></italic> as the log odds ratio between treatment <italic>k</italic> and placebo, with <italic>d</italic><sub>1</sub> = 0, and the Δ<sub><italic>Bk</italic></sub> can be replaced by <italic>d<sub>k</sub> − d<sub>B</sub></italic>. We assign a prior distribution to <italic>d<sub>k</sub></italic> rather than Δ<sub><italic>Bk</italic></sub>, and this can be used for our inferences regarding estimation and ranking of the treatment effects.</p>
<p>Our first 3 models fit under the assumption of evidence consistency—namely, that the estimated effect sizes arising from direct and indirect comparisons are the same. For example, when we compare treatments 2 and 3, we assume <inline-formula id="inline-formula1-0272989X13481110">
<mml:math display="inline" id="math3-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>, where <italic>C</italic> indicates the common comparator treatment, Δ<sub>23</sub> is the direct comparison, and <inline-formula id="inline-formula2-0272989X13481110">
<mml:math display="inline" id="math4-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> is the indirect comparison. We first fit a purely <italic>fixed effects</italic> model as in (2) that further assumes all studies estimate the same effect size, and therefore there is no variability (heterogeneity) between studies. In this model, we assume the log odds ratios, Δ<sub><italic>Bk</italic></sub>, are the same in each study.</p>
<p>To allow heterogeneity between studies, random effects models may be considered. In this approach, Δ<sub><italic>Bk</italic></sub> is replaced with δ<sub><italic>iBk</italic></sub>, which represents a log odds ratio between treatment <italic>k</italic> and <italic>B</italic> in the <italic>i</italic>th study, and we assume an independent normal specification for the δ<sub><italic>iBk</italic></sub>, that is,</p>
<p>
<disp-formula id="disp-formula3-0272989X13481110">
<mml:math display="block" id="math5-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>B</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq3.tif"/>
</disp-formula>
</p>
<p>By assigning a distribution to δ<sub><italic>iBk</italic></sub>, the model can capture the variability among studies. In this random effects model, we assume homogeneous variance σ<sup>2</sup> across all <italic>k</italic> treatments; we call this a <italic>homogeneous random effects</italic> model. Alternatively, we can introduce heterogeneous variances <inline-formula id="inline-formula3-0272989X13481110">
<mml:math display="inline" id="math6-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>B</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> in (3), obtaining a <italic>heterogeneous random effects</italic> model. For a multiarm trial, there are more than 2 log odds ratios, and one should perhaps account for correlations among them. In this case, we assume the <bold>δ</bold><sub><italic>i</italic></sub> vector follows a multivariate normal distribution with common correlation of 0.5 across treatments, as suggested by Lu and Ades.<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref></sup></p>
<p>Our last Bayesian model allows for evidence inconsistency by adding an extra set of terms called <italic>w-</italic>factors into the model.<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref></sup> This approach captures the discrepancy between direct and indirect comparisons between 2 treatments (say, 2 and 3) as</p>
<p>
<disp-formula id="disp-formula4-0272989X13481110">
<mml:math display="block" id="math7-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>C</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>C</mml:mi>
<mml:mn>32</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq4.tif"/>
</disp-formula>
</p>
<p>where <italic>w<sub>C</sub></italic><sub>32</sub> is the <italic>w</italic>-factor between drugs 2 and 3 through the common comparator treatment <italic>C</italic>. One can only define the <italic>w</italic>-factor when the 3 relative effects (Δ<sub>23</sub>, Δ<sub>3<italic>C</italic></sub>, and Δ<sub>2<italic>C</italic></sub> in (4)) are estimable from independent studies. Here, we assume homogeneous variance for random effects and denote this model as the <italic>inconsistency random effects</italic> model. Note that we number the drugs alphabetically except for placebo (i.e., in our example, placebo is drug number 1, darifenacin is 2, fesoterodine is 3, etc). Our data permit addition of one inconsistency factor for the UI improvement outcome (<inline-formula id="inline-formula4-0272989X13481110">
<mml:math display="inline" id="math8-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>147</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>) and 4 <italic>w</italic>-factors for the discontinuation outcome (<inline-formula id="inline-formula5-0272989X13481110">
<mml:math display="inline" id="math9-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>124</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>, <inline-formula id="inline-formula6-0272989X13481110">
<mml:math display="inline" id="math10-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>147</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>, <inline-formula id="inline-formula7-0272989X13481110">
<mml:math display="inline" id="math11-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>148</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>, and <inline-formula id="inline-formula8-0272989X13481110">
<mml:math display="inline" id="math12-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>167</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>). For the continence outcome, we cannot fit this model because no inconsistency <italic>w</italic>-factors are identified by these data; there are not enough studies having independent sources of direct and indirect comparisons to make these factors estimable. Please see Web Appendix 1 for details of how to define <italic>w</italic>-factors for our data.</p>
<p>In Bayesian analysis, prior information can be explicitly incorporated. We investigate 2 sets of prior distributions: one fully noninformative (or “flat”) and another that encourages shrinkage of the random baseline effects toward their grand means. In the first approach, which we term <italic>Bayes1</italic>, the µ<sub><italic>iB</italic></sub> and <italic>d<sub>k</sub></italic> are assumed to have a normal prior distribution with mean 0 and variance 10000, a specification that is very vague (though still proper) and essentially treats them as distinct, fixed effects. For the standard deviation σ in a homogeneous random effects model, a Uniform(0.01,2) prior is adopted.<sup><xref ref-type="bibr" rid="bibr24-0272989X13481110">24</xref></sup> For the heterogeneous model, a more complex prior for σ<sub><italic>Bk</italic></sub> is introduced; namely, we set <inline-formula id="inline-formula9-0272989X13481110">
<mml:math display="inline" id="math13-0272989X13481110">
<mml:mrow>
<mml:mi>log</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>x</mml:mi>
<mml:mi>y</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>x</mml:mi>
<mml:mi>y</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, where <inline-formula id="inline-formula10-0272989X13481110">
<mml:math display="inline" id="math14-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>Uniform</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>01</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>x</mml:mi>
<mml:mi>y</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>ψ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, and ψ is a constant chosen to reflect a certain amount of heterogeneity among arms.<sup><xref ref-type="bibr" rid="bibr15-0272989X13481110">15</xref></sup> In our inconsistency model, since only 1 <italic>w</italic>-factor is defined for the UI improvement outcome, we assume <inline-formula id="inline-formula11-0272989X13481110">
<mml:math display="inline" id="math15-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>147</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>~</mml:mo>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>10000</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>. By contrast, we assume the <italic>w</italic>-factors for the discontinuation outcome to be distributed independently as <inline-formula id="inline-formula12-0272989X13481110">
<mml:math display="inline" id="math16-0272989X13481110">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, where <inline-formula id="inline-formula13-0272989X13481110">
<mml:math display="inline" id="math17-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>Uniform</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>01</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>.<sup><xref ref-type="bibr" rid="bibr25-0272989X13481110">25</xref></sup> Here, the upper bound of our uniform priors, 2, is large enough to be noninformative since σ<sub><italic>w</italic></sub> is a standard deviation of random effects on the log odds scale.</p>
<p>Turning to the second prior <italic>(Bayes2)</italic>, we change the prior on the µ<sub><italic>iB</italic></sub> to encourage their shrinkage toward their grand mean and thus borrow strength across the independent but similar trials. Under this prior, the µ<sub><italic>iB</italic></sub> are considered random effects distributed <inline-formula id="inline-formula14-0272989X13481110">
<mml:math display="inline" id="math18-0272989X13481110">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, where the hyperparameters <italic>m<sub>B</sub></italic> and τ have <inline-formula id="inline-formula15-0272989X13481110">
<mml:math display="inline" id="math19-0272989X13481110">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>10000</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> and Uniform(0.01,2) priors, respectively. Other parameters remain the same as in the noninformative prior case.</p>
<p>Regarding methods for Bayesian model choice, the deviance information criterion (DIC) is a hierarchical modeling generalization of the familiar Akaike information criterion (AIC) often used in scenarios like ours.<sup><xref ref-type="bibr" rid="bibr26-0272989X13481110">26</xref></sup> DIC is calculated by summing <inline-formula id="inline-formula16-0272989X13481110">
<mml:math display="inline" id="math20-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>D</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math></inline-formula>, a measure of goodness of fit having a posterior predictive interpretation, and <italic>p<sub>D</sub></italic>, an effective number of parameters capturing overall model “size.” DIC treats the model size as random, necessary in the presence of random effects. Smaller values of DIC correspond to preferred models, and a DIC difference of 5 or more is generally regarded as practically meaningful.<sup><xref ref-type="bibr" rid="bibr27-0272989X13481110">27</xref></sup></p>
<p>The primary goal of MTCs is often to identify the best treatment. Suppose superscript (<inline-formula id="inline-formula17-0272989X13481110">
<mml:math display="inline" id="math21-0272989X13481110">
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:math></inline-formula>) indicates an event and <inline-formula id="inline-formula18-0272989X13481110">
<mml:math display="inline" id="math22-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> is the marginal posterior probability of having event <inline-formula id="inline-formula19-0272989X13481110">
<mml:math display="inline" id="math23-0272989X13481110">
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:math></inline-formula> under treatment <italic>k</italic>, perhaps modeled with a logit function. Denoting the data on outcome <inline-formula id="inline-formula20-0272989X13481110">
<mml:math display="inline" id="math24-0272989X13481110">
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:math></inline-formula> by <inline-formula id="inline-formula21-0272989X13481110">
<mml:math display="inline" id="math25-0272989X13481110">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula>, a natural Bayesian summary to consider when the outcome has a positive interpretation (say, efficacy) is the posterior probability of being best under each outcome,</p>
<p>
<disp-formula id="disp-formula5-0272989X13481110">
<mml:math display="block" id="math26-0272989X13481110">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mi>k</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mtext>is</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>the</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>best</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>treatment</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mo stretchy="false">|</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msup>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>}</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>Pr</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtext>rank</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">|</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq5.tif"/>
</disp-formula>
</p>
<p>a quantity we denote by Best1. Note we simply change 1 to <italic>K</italic> when the outcome has a negative interpretation (say, adverse event). Similarly, one can calculate the probability of being the first or second best treatment, denoted by Best12, by replacing the right-hand side of <xref ref-type="disp-formula" rid="disp-formula5-0272989X13481110">equation (5)</xref> with <inline-formula id="inline-formula22-0272989X13481110">
<mml:math display="inline" id="math27-0272989X13481110">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtext>rank</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mtext>or</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">|</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math></inline-formula>, where again small ranks indicate best treatments.</p>
<p>Next, to integrate these univariate probabilities over all the end points and obtain one omnibus measure of “best,” we might use an overall, weighted score. Suppose that <inline-formula id="inline-formula23-0272989X13481110">
<mml:math display="inline" id="math28-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> for positive outcomes and <inline-formula id="inline-formula24-0272989X13481110">
<mml:math display="inline" id="math29-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> for negative outcomes, so that high values of <inline-formula id="inline-formula25-0272989X13481110">
<mml:math display="inline" id="math30-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> indicate the best condition. Define the overall score as</p>
<p>
<disp-formula id="disp-formula6-0272989X13481110">
<mml:math display="block" id="math31-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>S</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:munder>
<mml:mo>∑</mml:mo>
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:munder>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq6.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula26-0272989X13481110">
<mml:math display="inline" id="math32-0272989X13481110">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula> is the weight for outcome <inline-formula id="inline-formula27-0272989X13481110">
<mml:math display="inline" id="math33-0272989X13481110">
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:math></inline-formula>, and <inline-formula id="inline-formula28-0272989X13481110">
<mml:math display="inline" id="math34-0272989X13481110">
<mml:mrow>
<mml:munder>
<mml:mo>∑</mml:mo>
<mml:mrow>
<mml:mi>ℓ</mml:mi>
</mml:mrow>
</mml:munder>
<mml:msup>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math></inline-formula>. This score can be used to obtain overall Best1 and Best12 probabilities by replacing <inline-formula id="inline-formula29-0272989X13481110">
<mml:math display="inline" id="math35-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> by <italic>S<sub>k</sub></italic> in (5). Note that the weights are not estimated from the data but chosen by physicians or public health professionals based on their relative preferences among the outcomes. In our example, since our UI data have 2 efficacy outcomes and 1 safety outcome, we modify the overall score to</p>
<p>
<disp-formula id="disp-formula7-0272989X13481110">
<mml:math display="block" id="math36-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>S</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dry</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dis</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq7.tif"/>
</disp-formula>
</p>
<p>where <italic>w</italic> trades off efficacy and safety and <italic>w<sub>e</sub></italic> trades off the 2 efficacy measures. Here, <italic>dry, imp</italic>, and <italic>dis</italic> stand for continence, UI improvement, and discontinuation, respectively. We investigate 3 different weights for <italic>w</italic> and <italic>w<sub>e</sub></italic>, 0.5, 0.8, or 0.2.</p>
</sec>
<sec id="section5-0272989X13481110">
<title>Frequentist Approach</title>
<p>Commercial software programs for frequentist multivariate random-effects meta-analysis have recently been developed, although they have some idiosyncrasies when handling multiarm trials or incomparable baseline treatments.<sup><xref ref-type="bibr" rid="bibr28-0272989X13481110">28</xref>,<xref ref-type="bibr" rid="bibr29-0272989X13481110">29</xref></sup> Although standard frequentist meta-analysis programs (written in SAS, Stata, or R) typically use log odds ratios as data and assume a normal likelihood, they could in principle use the same binomial distribution for the event data as in (1) and the similar fixed and random effects models as in (2) and (3). Here, we alter the frequentist notation slightly to distinguish the 2 approaches. We can rewrite the frequentist fixed effects model as</p>
<p>
<disp-formula id="disp-formula8-0272989X13481110">
<mml:math display="block" id="math37-0272989X13481110">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>s</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq8.tif"/>
</disp-formula>
</p>
<p>where <italic>s<sub>i</sub></italic> is a fixed study-specific effect for baseline treatment and <italic>t<sub>k</sub></italic> is the log odds ratio between drug <italic>k</italic> and baseline treatment with <italic>t</italic><sub>1</sub> = 0.</p>
<p>For a random effects model, we can extend the logit model (8) to</p>
<p>
<disp-formula id="disp-formula9-0272989X13481110">
<mml:math display="block" id="math38-0272989X13481110">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>s</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq9.tif"/>
</disp-formula>
</p>
<p>where the vector <inline-formula id="inline-formula30-0272989X13481110">
<mml:math display="inline" id="math39-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi mathvariant="bold">v</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> of <italic>v<sub>ik</sub></italic> values has an independent multivariate normal distribution <inline-formula id="inline-formula31-0272989X13481110">
<mml:math display="inline" id="math40-0272989X13481110">
<mml:mrow>
<mml:mi>MVN</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo mathvariant="bold">,</mml:mo>
<mml:mi mathvariant="bold">Ω</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, with <italic>K</italic> × <italic>K</italic> covariance matrix <bold>Ω</bold>. We can assume <bold>Ω</bold> = σ<sup>2</sup><bold>I</bold><sub><italic>k</italic></sub>, where <bold>I</bold><sub><italic>k</italic></sub> is a <italic>K</italic>×<italic>K</italic> identity matrix, but this model is not recommended by Jones and others,<sup><xref ref-type="bibr" rid="bibr28-0272989X13481110">28</xref></sup> who object to its failure to account for correlation among the <italic>K</italic> treatments. Instead, we can borrow the random effects model as the context of the Lu and Ades<sup><xref ref-type="bibr" rid="bibr21-0272989X13481110">21</xref></sup> notation and assign the similar covariance matrix structure as the Bayesian random effects model has. The random effects model can be rewritten as</p>
<p>
<disp-formula id="disp-formula10-0272989X13481110">
<mml:math display="block" id="math41-0272989X13481110">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:munderover>
<mml:mo>∑</mml:mo>
<mml:mrow>
<mml:mi>j</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:munderover>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq10.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula32-0272989X13481110">
<mml:math display="inline" id="math42-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:munderover>
<mml:mo>∑</mml:mo>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:munderover>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, δ<sub><italic>i</italic>1</sub> = 1 for all <italic>i</italic>, and <inline-formula id="inline-formula33-0272989X13481110">
<mml:math display="inline" id="math43-0272989X13481110">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo><mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>iK</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>~</mml:mo>
<mml:mi>MVN</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo><mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="bold">Σ</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math></inline-formula>, with <inline-formula id="inline-formula34-0272989X13481110">
<mml:math display="inline" id="math44-0272989X13481110">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> covariance matrix <bold>Σ</bold>. In this notation, we have <inline-formula id="inline-formula35-0272989X13481110">
<mml:math display="inline" id="math45-0272989X13481110">
<mml:mrow>
<mml:mi mathvariant="bold">Ω</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi mathvariant="bold">A</mml:mi>
<mml:mi mathvariant="bold">Σ</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mi mathvariant="bold">A</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula>, where <bold>A</bold> is a <inline-formula id="inline-formula36-0272989X13481110">
<mml:math display="inline" id="math46-0272989X13481110">
<mml:mrow>
<mml:mi>K</mml:mi>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> matrix, and the (<italic>i, j</italic>)th element of the <bold>A</bold> is <inline-formula id="inline-formula37-0272989X13481110">
<mml:math display="inline" id="math47-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>A</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>j</mml:mi>
<mml:mo>+</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math></inline-formula>, where <italic>I</italic> denotes the indicator function. One can assign particular structures for Σ, but many authors recommend simple specifications such as homogeneous variances and 0.5 correlation across all arms. We refer to this model as the frequentist homogeneous random effects model. Jones and others<sup><xref ref-type="bibr" rid="bibr28-0272989X13481110">28</xref></sup> use (10) to construct various covariance matrices by varying the design matrix <bold>A</bold> and provide details on such selections.</p>
<p>We can loosen the homogeneous variability assumption and fit a frequentist heterogeneous random effects model using a frequentist approach via standard commercial software.<sup><xref ref-type="bibr" rid="bibr29-0272989X13481110">29</xref></sup> The model can be specified same as the Bayesian random effects model <inline-formula id="inline-formula38-0272989X13481110">
<mml:math display="inline" id="math48-0272989X13481110">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ik</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> with <inline-formula id="inline-formula39-0272989X13481110">
<mml:math display="inline" id="math49-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for all <italic>i</italic>, and <inline-formula id="inline-formula40-0272989X13481110">
<mml:math display="inline" id="math50-0272989X13481110">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo><mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>iK</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>~</mml:mo>
<mml:mi>MVN</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo><mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>K</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>,</mml:mo><mml:mi mathvariant="bold">Σ</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math></inline-formula>, where again <bold>Σ</bold> is an unstructured <inline-formula id="inline-formula41-0272989X13481110">
<mml:math display="inline" id="math51-0272989X13481110">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>K</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> covariance matrix. We can estimate <bold>Σ</bold> by likelihood-based methods provided the data contain at least some information on every drug-by-drug relation.</p>
<p>To measure inconsistency, although we cannot estimate <italic>w</italic>-factors statistically by adding them into the model, we can compare the separately estimated direct and indirect effect sizes (Δ<sub>23</sub> and Δ<sub>3<italic>C</italic></sub>–Δ<sub>2<italic>C</italic></sub> in (4), respectively). That is, we use partial data including only those specific relations to estimate each relative effect; note this method cannot simultaneously incorporate all the uncertainty in our data.</p>
<p>In frequentist approaches, it is not immediately clear how to produce a ranking metric that reflects all 3 point estimators and their uncertainties, such as the Bayesian Best1 or Best12 probability in (6). Log odds ratios (or odds ratios) between drugs and placebo are usually used for an inference about drugs. We can first obtain maximum likelihood estimators (MLEs) of <italic>d<sub>k</sub></italic> and <bold>Σ</bold>, denoted by <inline-formula id="inline-formula42-0272989X13481110">
<mml:math display="inline" id="math52-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula43-0272989X13481110">
<mml:math display="inline" id="math53-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow><mml:mi mathvariant="bold">Σ</mml:mi></mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math></inline-formula>, and then calculate the 95% classical confidence intervals of <italic>d<sub>k</sub></italic> with their standard deviations, the square roots of the diagonal elements of <inline-formula id="inline-formula44-0272989X13481110">
<mml:math display="inline" id="math54-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow><mml:mi mathvariant="bold">Σ</mml:mi></mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math></inline-formula>. To compare with the Bayesian ranks obtained from (7) for our UI data, we use a similar overall score but replace <inline-formula id="inline-formula45-0272989X13481110">
<mml:math display="inline" id="math55-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>ℓ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> with <inline-formula id="inline-formula46-0272989X13481110">
<mml:math display="inline" id="math56-0272989X13481110">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>. That is, we define a frequentist weighted log odds ratio (WLOR) as</p>
<p>
<disp-formula id="disp-formula11-0272989X13481110">
<mml:math display="block" id="math57-0272989X13481110">
<mml:mrow>
<mml:mtext>WLO</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>R</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msubsup>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dry</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dis</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula11-0272989X13481110" xlink:href="10.1177_0272989X13481110-eq11.tif"/>
</disp-formula>
</p>
<p>where the definitions of the weights <italic>w</italic> and <italic>w<sub>e</sub></italic> are the same as before. Here, since the discontinuation outcome has a negative meaning, we change the direction of <inline-formula id="inline-formula47-0272989X13481110">
<mml:math display="inline" id="math58-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dis</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> so that larger WLOR<sub><italic>k</italic></sub> indicates a better drug in terms of both efficacy and safety.</p>
</sec>
<sec id="section6-0272989X13481110">
<title>Computing and Software</title>
<p>All of our Bayesian results were obtained from the WinBUGS software,<sup><xref ref-type="bibr" rid="bibr30-0272989X13481110">30</xref></sup> using 2 parallel chains of 50,000 Markov chain Monte Carlo (MCMC) samples after a 50,000-sample burn-in. To check MCMC convergence, we used standard diagnostics, including trace plots and lag 1 sample autocorrelations.</p>
<p>We can fit a frequentist fixed and homogeneous random effects model using Proc GLIMMIX in SAS 9.2 software (SAS Institute, Cary, NC) to obtain maximum likelihood estimators with 95% confidence limits.<sup><xref ref-type="bibr" rid="bibr28-0272989X13481110">28</xref></sup> Stata (release 12; StataCorp, College Station, TX) can fit the frequentist heterogeneous random effects model using mvmeta,<sup><xref ref-type="bibr" rid="bibr29-0272989X13481110">29</xref></sup> but unfortunately, Stata cannot fit this model with our UI data since they are too sparse to estimate MLE of all elements of the covariance matrix. We provide both BUGS and SAS codes in Web Appendix 2.</p>
</sec>
<sec id="section7-0272989X13481110">
<title>Role of Funding Source</title>
<p>Our work was funded by Agency for Healthcare Research and Quality (AHRQ) contract 290-2007-10064 I2, project ID MNE3206, “Bayesian Approa-ches to Indirect Comparisons.” The role of the funding source was to provide partial salary support for the first and second authors to develop the methods, computer code, and manuscript reporting the results. The source also supported the fuller version of this work reported in Carlin and others,<sup><xref ref-type="bibr" rid="bibr31-0272989X13481110">31</xref></sup> which also includes further details on derivation of our models and more extensive results of the UI data analysis with graphs of bivariate ranks.</p>
</sec>
</sec>
<sec id="section8-0272989X13481110" sec-type="results">
<title>Results</title>
<p><xref ref-type="table" rid="table2-0272989X13481110">Table 2</xref> uses DIC and its components to compare 8 Bayesian models (4 models each with 2 possible priors; 6 Bayesian models for the continence outcome) for our UI data. For the continence outcome, random effects models do not appear to offer much benefit, due to small random effect variability (median posterior of σ is 0.07) and high shrinkage (low <italic>p<sub>D</sub></italic>) even under the vague Bayes1 prior. However, for the other 2 outcomes, a decrease in DIC mainly resulting from small fit statistic <inline-formula id="inline-formula48-0272989X13481110">
<mml:math display="inline" id="math59-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>D</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math></inline-formula> arises between the fixed and random effects models with slightly larger random effect variability (<inline-formula id="inline-formula49-0272989X13481110">
<mml:math display="inline" id="math60-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>17</mml:mn>
</mml:mrow>
</mml:math></inline-formula> and 0.25 for the UI improvement and discontinuation outcomes, respectively). The homogeneous and heterogeneous random effects models give almost the same DIC for all outcomes. Generally, the homogeneous random effects model offers the best compromise between fit and complexity (i.e., lowest DIC); neither the addition of <italic>w</italic>-factors nor heterogeneous variances pay practically significant improvements in DIC. As such, for Bayesian decision making, we adopt the homogeneous random effects models with both priors. Regarding the 2 priors, although the shrinkage prior (Bayes2) always produces smaller DIC than the noninformative prior, we see no meaningful difference in DIC except roughly a 5-unit decrease for the discontinuation outcome, resulting from a roughly 10-unit decrease in <italic>p<sub>D</sub></italic> across all models. For this outcome, the shrinkage encouraged by Bayes2 implies lower model complexity.</p>
<table-wrap id="table2-0272989X13481110" position="float">
<label>Table 2</label>
<caption>
<p>Bayesian model comparison for urinary incontinence (UI) data</p>
</caption>
<graphic alternate-form-of="table2-0272989X13481110" xlink:href="10.1177_0272989X13481110-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th colspan="2"/>
<th align="center" colspan="6">Random Effects Model<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Fixed Effects Model<hr/></th>
<th align="center" colspan="2">Homogeneous<hr/></th>
<th align="center" colspan="2">Heterogeneous<hr/></th>
<th align="center" colspan="2">Inconsistency<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="center">Bayes1</th>
<th align="center">Bayes2</th>
<th align="center">Bayes1</th>
<th align="center">Bayes2</th>
<th align="center">Bayes1</th>
<th align="center">Bayes2</th>
<th align="center">Bayes1</th>
<th align="center">Bayes2</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">Continence</td>
<td>
<inline-formula id="inline-formula50-0272989X13481110">
<mml:math display="inline" id="math61-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>D</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>259.6</td>
<td>259.6</td>
<td>258.2</td>
<td>258.1</td>
<td>258.2</td>
<td>258.2</td>
<td align="center">NA</td>
<td align="center">NA</td>
</tr>
<tr>
<td>
<italic>p<sub>D</sub></italic>
</td>
<td>25</td>
<td>24.2</td>
<td>27.9</td>
<td>27.1</td>
<td>27.9</td>
<td>27</td>
<td align="center">NA</td>
<td align="center">NA</td>
</tr>
<tr>
<td>DIC</td>
<td>284.6</td>
<td>283.8</td>
<td>286.1</td>
<td>285.2</td>
<td>286.1</td>
<td>285.2</td>
<td align="center">NA</td>
<td align="center">NA</td>
</tr>
<tr>
<td rowspan="3">UI improvement</td>
<td>
<inline-formula id="inline-formula51-0272989X13481110">
<mml:math display="inline" id="math62-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>D</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>405.6</td>
<td>405.9</td>
<td>388.8</td>
<td>388.5</td>
<td>389</td>
<td>388.4</td>
<td>388.8</td>
<td>388.4</td>
</tr>
<tr>
<td>
<italic>p<sub>D</sub></italic>
</td>
<td>35</td>
<td>34.4</td>
<td>45.3</td>
<td>45.2</td>
<td>45.7</td>
<td>45.4</td>
<td>46</td>
<td>45.9</td>
</tr>
<tr>
<td>DIC</td>
<td>440.6</td>
<td>440.3</td>
<td>434.1</td>
<td>433.7</td>
<td>434.7</td>
<td>433.8</td>
<td>434.8</td>
<td>434.3</td>
</tr>
<tr>
<td rowspan="3">Discontinuation</td>
<td>
<inline-formula id="inline-formula52-0272989X13481110">
<mml:math display="inline" id="math63-0272989X13481110">
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>D</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>547.5</td>
<td>548.9</td>
<td>531.7</td>
<td>536.7</td>
<td>529.4</td>
<td>534.4</td>
<td>531.7</td>
<td>536.6</td>
</tr>
<tr>
<td>
<italic>p<sub>D</sub></italic>
</td>
<td>53.7</td>
<td>45.6</td>
<td>67</td>
<td>56.1</td>
<td>67.9</td>
<td>57.1</td>
<td>68.3</td>
<td>57.7</td>
</tr>
<tr>
<td>DIC</td>
<td>601.2</td>
<td>594.5</td>
<td>598.7</td>
<td>592.8</td>
<td>597.3</td>
<td>591.5</td>
<td>600</td>
<td>594.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X13481110">
<p>Smaller deviance information criterion (DIC) means better fit. NA, not applicable.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="fig2-0272989X13481110">Figure 2</xref> exhibits odds ratios between drugs and placebo (posterior median and MLE for Bayesian and frequentist models, respectively) with 95% credible or confidence intervals for each outcome from 4 of the models: the Bayesian fixed effects model with the Bayes2 prior (FE_Bayes2), the frequentist homogeneous random effects model (RE_freq), and the Bayesian homogeneous random effects model under both Bayes1 (RE_Bayes1) and Bayes2 priors (RE_Bayes2). The best drug based on each parameter in each outcome from each model is shown with a square character, and the worst drug is shown with a triangle. Note that the smaller odds ratios indicate more acceptable (safer) drugs under the discontinuation outcome. For the continence outcome, all of the odds ratios are significantly greater than 1 (i.e., all drugs are more effective than placebo), and propiverine and trospium have estimated odds ratios close to 2, meaning that being treated with either of these leads to about 2 times greater odds of continence compared with being untreated. However, there appear to be no significant differences between drugs. Regarding the UI improvement outcome, the odds ratios of oxybutynin, propiverine, and solifenacin exceed 2, whereas tolterodine delivers the worst performance, although again no drugs are significantly different. For the discontinuation outcome, tolterodine is the safest drug and oxybutynin performs worst. There are just 2 significant differences between drugs: tolterodine v. oxybutynin and fesoterodine (their 95% intervals do not overlap). Note that the odds ratios for propiverine emerge as having very wide intervals because there are only 2 studies of the relation between this drug and placebo, and they do not agree regarding its safety.</p>
<fig id="fig2-0272989X13481110" position="float">
<label>Figure 2</label>
<caption>
<p>Urinary incontinence (UI) data interval plot of odds ratios between drugs and placebo for each outcome under 4 models. FE_Bayes2: Bayesian fixed effects model with shrinkage prior; RE_freq: frequentist homogeneous random effects model; RE_Bayes1: Bayesian homogeneous random effects model with noninformative prior; RE_Bayes2: Bayesian homogeneous random effects model with shrinkage prior.</p>
</caption>
<graphic xlink:href="10.1177_0272989X13481110-fig2.tif"/>
</fig>
<p>Bayesian and frequentist homogeneous random effects models deliver similar findings with similar odds ratios. However, the frequentist model tends to underestimate the random effect variability relative to the Bayesian; the estimated σ values in frequentist random effects models are 0, 0.1, and 0 for the continence, UI improvement, and discontinuation outcomes, respectively. On the other hand, the inconsistency implied by the frequentist method is somewhat larger than that of the Bayesian. In the Bayesian inconsistency random effects model, the estimated median posterior <italic>w</italic>-factors are small (<inline-formula id="inline-formula53-0272989X13481110">
<mml:math display="inline" id="math64-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>w</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mn>147</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>36</mml:mn>
</mml:mrow>
</mml:math></inline-formula> with respect to the UI improvement outcome, and all <italic>w</italic>-factors under the Bayes1 prior are smaller than 0.02 for the discontinuation outcome), implying minimal inconsistency between direct and indirect comparisons. However, for the discontinuation outcome, the difference between directly and indirectly estimated <italic>d<sub>k</sub></italic> ranges from −0.15 to 0.63 under the frequentist approach. Although these estimates are not statistically significant due to large standard errors, the Bayesian inconsistency estimates more accurately reflect the true uncertainty in the data than the frequentist estimates.</p>
<p><xref ref-type="fig" rid="fig3-0272989X13481110">Figure 3</xref> displays the Bayesian posterior probabilities of each drug, taking each possible ranking from 1 (best) to 8 (worst) (1 to 7 for the continence outcome due to the absence of a darifenacin arm) for the 3 outcomes.<sup><xref ref-type="bibr" rid="bibr32-0272989X13481110">32</xref></sup> Although these graphs cannot reveal significant differences in rankings among drugs or the magnitudes of any drugs differences, they do still give a sense of the uncertainty in the rank for each drug. Placebo’s probability of being the safest drug is roughly 0.9, leaving the remaining 7 drugs to share the remaining 0.1 probability of being safest. Taking this into consideration, propiverine performs pretty well in terms of both efficacy outcomes (solid and dashed lines) and moderately for safety (dotted line). Solifenacin and trospium show high probabilities of being the first or second best in terms of either the UI improvement or continence outcome and fair probabilities of being the first or second safest. Tolterodine emerges as the safest among nonplacebo drugs but also the least effective among this class. Rankings for safety excluding placebo could of course also be obtained.</p>
<fig id="fig3-0272989X13481110" position="float">
<label>Figure 3</label>
<caption>
<p>Rankogram of urinary incontinence (UI) drugs for each outcome under the Bayesian homogeneous random effects model with the shrinkage prior.</p>
</caption>
<graphic xlink:href="10.1177_0272989X13481110-fig3.tif"/>
</fig>
<p><xref ref-type="table" rid="table3-0272989X13481110">Table 3</xref> shows Best12 probabilities using the weighted score in (7) under the Bayesian homogeneous random effects model with the shrinkage prior (upper part) and the WLOR<sub><italic>k</italic></sub> in (11) under the frequentist homogeneous random effects model (lower part). Note that we consider the effect of darifenacin for the continence outcome to be the same as that of the placebo in this table. In the Bayesian analysis, propiverine emerges as the best compromise between efficacy and safety across all different weights except when <italic>w</italic> = 0.2 and <italic>w<sub>e</sub></italic> = 0.8 (where it is a close runner-up to trospium). By contrast, the frequentist results are much less consistent across weighting methods, with propiverine emerging as the best or second best drug only when <italic>w</italic> = 0.8. Under the “safety weights” (<italic>w</italic> = 0.2), placebo emerges as best overall, defeating even the quite safe and marginally effective tolterodine and several other drugs with significant efficacy against placebo. The reason why the safety weights have a smaller impact under the Bayesian approach is that the differences in marginal probability <inline-formula id="inline-formula54-0272989X13481110">
<mml:math display="inline" id="math65-0272989X13481110">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>P</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>dis</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> in (7) between drugs are so minimal that the 2 efficacy measures dominate the determination of the Best12 probabilities. However, since the WLOR<sub><italic>k</italic></sub> directly uses the log odds ratios, it fails to react to the small magnitudes of the probabilities of discontinuation, which then have a disproportionate influence on the ranking. As a check on our ranks, we recomputed the Bayesian and frequentist rankings after assuming that darifenacin had the same effect on the continence outcome as that of either tolterodine or propiverine (the worst and best drugs for the outcome, respectively). The former case did not change the rankings at all, whereas the latter yielded darifenacin among the top 3 under the safety weights, resulting from its smaller odds ratio in terms of the discontinuation outcome.</p>
<table-wrap id="table3-0272989X13481110" position="float">
<label>Table 3</label>
<caption>
<p>Decision making of urinary incontinence (UI) data: Best12 probability with weighted score under the Bayesian homogeneous random effects model with the shrinkage prior and the frequentist weighted log odds ratio (WLOR<sub><italic>k</italic></sub>)</p>
</caption>
<graphic alternate-form-of="table3-0272989X13481110" xlink:href="10.1177_0272989X13481110-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3"><italic>w</italic> = 0.5<hr/></th>
<th align="center" colspan="3"><italic>w</italic> = 0.8<hr/></th>
<th align="center" colspan="3"><italic>w</italic> = 0.2<hr/></th>
</tr>
<tr>
<th/>
<th align="center"><italic>w<sub>e</sub></italic> = 0.5</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.8</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.2</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.5</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.8</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.2</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.5</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.8</th>
<th align="center"><italic>w<sub>e</sub></italic> = 0.2</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="10">Best12 probability</td>
</tr>
<tr>
<td> Placebo</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.001</td>
<td>0.004</td>
<td>0</td>
</tr>
<tr>
<td> Darifenacin</td>
<td>0.003</td>
<td>0.000</td>
<td>0.066</td>
<td>0.001</td>
<td>0.000</td>
<td>0.029</td>
<td>0.093</td>
<td>0.016</td>
<td>0.246</td>
</tr>
<tr>
<td> Fesoterodine</td>
<td>0.07</td>
<td>0.082</td>
<td>0.07</td>
<td>0.105</td>
<td>0.142</td>
<td>0.093</td>
<td>0.01</td>
<td>0.012</td>
<td>0.01</td>
</tr>
<tr>
<td> Oxybutynin</td>
<td>0.228</td>
<td>0.215</td>
<td>0.251</td>
<td>0.448</td>
<td>0.405</td>
<td>0.460</td>
<td>0.007</td>
<td>0.009</td>
<td>0.009</td>
</tr>
<tr>
<td> Propiverine</td>
<td>
<bold>0.816</bold>
</td>
<td>
<bold>0.722</bold>
</td>
<td>
<bold>0.807</bold>
</td>
<td>
<bold>0.810</bold>
</td>
<td>
<bold>0.726</bold>
</td>
<td>
<bold>0.790</bold>
</td>
<td>
<bold>0.601</bold>
</td>
<td>0.548</td>
<td>
<bold>0.615</bold>
</td>
</tr>
<tr>
<td> Solifenacin</td>
<td>0.604</td>
<td>0.416</td>
<td>0.636</td>
<td>0.453</td>
<td>0.296</td>
<td>0.513</td>
<td>0.566</td>
<td>0.452</td>
<td>0.597</td>
</tr>
<tr>
<td> Tolterodine</td>
<td>0.006</td>
<td>0.011</td>
<td>0.007</td>
<td>0</td>
<td>0.001</td>
<td>0.000</td>
<td>0.355</td>
<td>0.372</td>
<td>0.297</td>
</tr>
<tr>
<td> Trospium</td>
<td>0.272</td>
<td>0.554</td>
<td>0.163</td>
<td>0.184</td>
<td>0.43</td>
<td>0.115</td>
<td>0.368</td>
<td>
<bold>0.587</bold>
</td>
<td>0.225</td>
</tr>
<tr>
<td colspan="10">WLOR<sub><italic>k</italic></sub></td>
</tr>
<tr>
<td> Placebo</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>
<bold>0.000</bold>
</td>
<td>
<bold>0.000</bold>
</td>
<td>
<bold>0.000</bold>
</td>
</tr>
<tr>
<td> Darifenacin</td>
<td>–0.027</td>
<td>–0.106</td>
<td>0.051</td>
<td>0.146</td>
<td>0.02</td>
<td>0.272</td>
<td>–0.201</td>
<td>–0.232</td>
<td>–0.169</td>
</tr>
<tr>
<td> Fesoterodine</td>
<td>–0.092</td>
<td>–0.112</td>
<td>–0.073</td>
<td>0.331</td>
<td>0.299</td>
<td>0.362</td>
<td>–0.515</td>
<td>–0.523</td>
<td>–0.507</td>
</tr>
<tr>
<td> Oxybutynin</td>
<td>–0.051</td>
<td>–0.07</td>
<td>–0.033</td>
<td>0.423</td>
<td>0.393</td>
<td>0.452</td>
<td>–0.525</td>
<td>–0.532</td>
<td>–0.518</td>
</tr>
<tr>
<td> Propiverine</td>
<td>0.041</td>
<td>0.006</td>
<td>0.076</td>
<td>
<bold>0.484</bold>
</td>
<td>0.429</td>
<td>
<bold>0.540</bold>
</td>
<td>–0.402</td>
<td>–0.416</td>
<td>–0.388</td>
</tr>
<tr>
<td> Solifenacin</td>
<td>
<bold>0.109</bold>
</td>
<td>0.082</td>
<td>
<bold>0.136</bold>
</td>
<td>0.456</td>
<td>0.412</td>
<td>0.499</td>
<td>–0.239</td>
<td>–0.249</td>
<td>–0.228</td>
</tr>
<tr>
<td> Tolterodine</td>
<td>0.096</td>
<td>0.079</td>
<td>0.113</td>
<td>0.275</td>
<td>0.248</td>
<td>0.303</td>
<td>–0.083</td>
<td>–0.09</td>
<td>–0.077</td>
</tr>
<tr>
<td> Trospium</td>
<td>0.104</td>
<td>
<bold>0.116</bold>
</td>
<td>0.091</td>
<td>0.437</td>
<td>
<bold>0.458</bold>
</td>
<td>0.417</td>
<td>–0.23</td>
<td>–0.225</td>
<td>–0.235</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0272989X13481110">
<p>The “best” treatment is in bold.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In summary, taking into account all efficacy and safety outcomes, solifenacin, propiverine, trospium, and placebo all emerge as most likely to be among the best or second best drugs in our frequentist analysis, whereas propiverine is consistently best overall in this respect in the Bayesian analysis, where its relatively poor but still acceptable (and imprecisely estimated) safety record is downweighted. Although the frequentist and Bayesian analyses produce broadly comparable odds ratios for safety and efficacy, the Bayesian method is able to deliver the probability that any drug is among the top 2 such drugs while accounting for the overall size and their uncertainties of those probabilities. This leads to a better ranking, as well as a more meaningful clinical interpretation for patients, doctors, and other stakeholders. However, we caution that for these data, there is a general lack of statistically significant differences among the drugs even in the Bayesian analysis.</p>
</sec>
<sec id="section9-0272989X13481110" sec-type="discussion">
<title>Discussion</title>
<p>The main objective of this paper has been to compare Bayesian and frequentist MTC methodologies in a challenging case study, rather than offer a full comparative clinical assessment. Generally, our results indicate that, although Bayesian methods require more assumptions (especially the selection of appropriate prior distributions), they are more flexible (especially for ranking), are more consistent, and also provide substantially more information useful for clinicians and health policy makers. From the standpoint of theory, Bayesian methods are also appealing due to their more rigorous mathematical foundations and their ability to incorporate all available sources of information in a model-based framework, rather than simply attempt to combine statistical summaries (say across 2 different outcomes) in an ad hoc way. From a more practical point of view, Bayesian methods offer direct probability statements about outcome variables, such as the probability that one drug is the best or among the top 2 drugs for an indication, or the probability of experiencing a particular end point (or combination of multiple end points with subjective weights) given the patient has taken a particular drug. By contrast, although we created weighted log odds ratios in our example, frequentist analyses rely on traditional notions of statistical significance and therefore do not provide an estimate of the probability of being the best drug. The Bayesian methods remedy this shortcoming, furthering patient-centered research by replacing hard-to-understand <italic>P</italic> values with intuitive Best1 and Best12 probabilities.</p>
<p>Thanks to methodological and computational development in frequentist MTCs, we can fit frequentist fixed and random effects models that are broadly comparable to Bayesian models. However, there are some limitations in the commercial software often used to implement frequentist analysis. Handling study arms with zero events is always problematic, and our UI data contain such studies. One can augment the data by adding 1 individual with 0.5 successes to an arm containing zero events or simply exclude studies with no events at all, but both methods have potentially harmful impacts on the asymptotic approximations these programs use to determine statistical significance.<sup><xref ref-type="bibr" rid="bibr33-0272989X13481110">33</xref></sup> Although we could not fit the frequentist heterogeneous random effects model with our UI data, Stata requires manipulating the data set to make all studies have the same baseline treatment (say, placebo) by including 0.01 artificial individuals and 0.001 artificial successes for the missing placebo arms. Also, when we have sparse data, we cannot fit this model at all since there is not enough information to estimate all the elements of the unstructured covariance matrix, whereas the Bayesian method remains feasible since a weakly informative prior can be used for any elements of the covariance matrix inestimable from data.</p>
<p>In frequentist analysis with our UI data, the estimates of random effect variability, σ, are always smaller than in Bayesian analysis (and, for continence and discontinuation, were essentially zero). To measure inconsistency, frequentist methods use log odds ratios estimated from studies including direct comparisons and indirect comparisons separately and compare these quantities. However, Bayesian analysis allows us to measure the amount of inconsistency statistically with <italic>w</italic>-factors, although the estimation of their variance is typically very imprecise. Other methods have been recommended for networks with few evidence loops, such as the node-split or other simpler approaches.<sup><xref ref-type="bibr" rid="bibr25-0272989X13481110">25</xref></sup> Some inconsistencies calculated in frequentist analysis are overestimated relative to the corresponding <italic>w</italic>-factors in the Bayesian method. Also, in <xref ref-type="fig" rid="fig2-0272989X13481110">Figure 2</xref>, the standard errors of the odds ratios are slightly smaller than those from the Bayesian models and produce less consistent conclusions across weighting schemes. These findings generally agree with those of Jones and others.<sup><xref ref-type="bibr" rid="bibr28-0272989X13481110">28</xref></sup></p>
<p>In the specific context of our UI data, both frequentist and Bayesian meta-analyses conclude that most of the drugs were better than placebo in achieving continence and improving UI. Bayesian analysis provides an intuitively appealing probability of the outcome that easily leads to identifying the best and worst treatment for each measure of benefit or harm, as well as facilitates a single estimate of the balance between benefits and harms useful for making informed overall decisions. Sensible weights for each outcome permit finding the best overall drug in terms of one’s preference (i.e., a clinician might well put more weight on safety than efficacy). Of course, a sensible threshold for the probability for being the most effective and safest drug may vary depending on the topic and the appropriateness of the model and prior, which may of course be checked statistically. A similar weighting strategy applied to log odds ratios can also identify a best drug, but such frequentist approaches cannot deliver probabilities of being the first or second best drug. Also, such rankings are more easily overinterpreted, since statistically significant differences between drugs on the log odds scale may be practically insignificant when viewed on the event probability scale (this led to placebo actually emerging as “best” in 3 spots in <xref ref-type="table" rid="table3-0272989X13481110">Table 3</xref>). We remark that the (primarily frequentist) Stata program mvmeta actually uses a flat-prior approximate Bayesian method to estimate probabilities of being best.</p>
<p>Although we have considered a fairly broad range of binary data Bayesian methods, our analysis still has limitations. First, we considered only noninformative and shrinkage priors. Although our shrinkage prior is partially informative, we did not incorporate specific prior information regarding efficacy or safety for any drug, due to limited information about the natural history of urgency UI. We could construct informative priors based on either external data or expert opinion, possibly leading to better-fitting models. Second, our choice of safety end point (discontinuation due to AEs) could be problematic because AE definitions could vary across study protocols; for example, our analysis did not consider less severe AEs, such as dry mouth or constipation. Third, because we assumed patients assigned to different drugs across studies had similar baseline characteristics, our results could be sensitive to departures from this assumption. For instance, we did not adjust for study quality (say, due to differences in randomization methods or publication bias), the role of the drug within the RCTs (experimental v. standard of care), doses of the drugs, and average ages of the women, their baseline UI severities, or their natural histories of urgency UI.</p>
<p>In summary, we believe that a Bayesian approach to MTC analysis is preferable to traditional frequentist approaches since it is more straightforward conceptually, permits using all available data, and produces richer and more easily interpretable results. The Bayesian approach also makes it easier to extend simple and naive MTC models to more complex but reasonable models and offers a more natural metric for decision making (e.g., the probability that a given drug is best or among the top 2). Future development in this field looks to extending our approach for combiningefficacy and safety data to incorporate and model the relationships (i.e., statistical correlations) among these multiple end points to arrive at an even more sensible overall decision. Additional scope for modeling lies in the incorporation of patient-level data<sup><xref ref-type="bibr" rid="bibr34-0272989X13481110">34</xref></sup> with individual-level covariates, possibly in concert with standard trial-level summaries from the published literature, to investigate subject-specific effects and further improve our understanding of the absolute and relative effects of the treatments.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Supplementary material for this article is available on the <italic>Medical Decision Making</italic> Web site at <ext-link ext-link-type="uri" xlink:href="http://mdm.sagepub.com/supplemental">http://mdm.sagepub.com/supplemental</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X13481110">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Basu</surname><given-names>A</given-names></name>
</person-group>. <article-title>Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care</article-title>. <source>J Health Econ</source>. <year>2011</year>;<volume>30</volume>(<issue>3</issue>):<fpage>549</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X13481110">
<label>2.</label>
<citation citation-type="web">
<collab>Committee on Comparative Effectiveness Research Prioritization, Institute of Medicine</collab>. <article-title>Initial National Priorities for Comparative Effectiveness Research</article-title>. <day>30</day> <month>June</month> <year>2009</year>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nap.edu/catalog/12648.html">http://www.nap.edu/catalog/12648.html</ext-link></citation>
</ref>
<ref id="bibr3-0272989X13481110">
<label>3.</label>
<citation citation-type="web">
<collab>Brookings Institution</collab>. <article-title>Implementing Comparative Effectiveness Research: Priorities, Methods, and Impact</article-title>. <source>The Hamilton Project</source>. <year>2009</year> <month>June</month>:<fpage>1</fpage>–<lpage>88</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hamiltonproject.org/papers/">http://www.hamiltonproject.org/papers/</ext-link></citation>
</ref>
<ref id="bibr4-0272989X13481110">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coory</surname><given-names>M</given-names></name>
<name><surname>Jordan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Frequency of treatment-effect modification affecting indirect comparisons: a systematic review</article-title>. <source>Pharmcoeconomics</source>. <year>2010</year>;<volume>28</volume>(<issue>9</issue>):<fpage>723</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X13481110">
<label>5.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Wells</surname><given-names>G</given-names></name>
<name><surname>Sultan</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Indirect evidence: indirect treatment comparisons in meta-analysis</article-title>. <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>. <year>2009</year>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cadth.ca/media/pdf/H0462_itc_tr_e.pdf">http://www.cadth.ca/media/pdf/H0462_itc_tr_e.pdf</ext-link></citation>
</ref>
<ref id="bibr6-0272989X13481110">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glenny</surname><given-names>AM</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
<name><surname>Song</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Indirect comparisons of competing interventions</article-title>. <source>Health Technol Assess</source>. <year>2005</year>;<volume>9</volume>(<issue>26</issue>):<fpage>1</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X13481110">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>F</given-names></name>
<name><surname>Loke</surname><given-names>YK</given-names></name>
<name><surname>Walsh</surname><given-names>T</given-names></name>
<name><surname>Glenny</surname><given-names>AM</given-names></name>
<name><surname>Eastwood</surname><given-names>AJ</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>338</volume>:<fpage>b1147</fpage>.</citation>
</ref>
<ref id="bibr8-0272989X13481110">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donegan</surname><given-names>S</given-names></name>
<name><surname>Williamson</surname><given-names>P</given-names></name>
<name><surname>Gamble</surname><given-names>C</given-names></name>
<name><surname>Tudur-Smith</surname><given-names>C</given-names></name>
</person-group>. <article-title>Indirect comparisons: a review of reporting and methodological quality</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>11</issue>):<fpage>e11054</fpage>.</citation>
</ref>
<ref id="bibr9-0272989X13481110">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lumley</surname><given-names>T</given-names></name>
</person-group>. <article-title>Network meta-analysis for indirect treatment comparisons</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>16</issue>):<fpage>2313</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X13481110">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jansen</surname><given-names>JP</given-names></name>
<name><surname>Fleurence</surname><given-names>R</given-names></name>
<name><surname>Devine</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1</article-title>. <source>Value Health</source>. <year>2011</year>;<volume>14</volume>(<issue>4</issue>):<fpage>417</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X13481110">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoaglin</surname><given-names>DC</given-names></name>
<name><surname>Hawkins</surname><given-names>N</given-names></name>
<name><surname>Jansen</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2</article-title>. <source>Value Health</source>. <year>2011</year>;<volume>14</volume>(<issue>4</issue>):<fpage>429</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X13481110">
<label>12.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Shamliyan</surname><given-names>T</given-names></name>
<name><surname>Wyman</surname><given-names>J</given-names></name>
<name><surname>Kane</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review No. 36</article-title>. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. <publisher-loc>Rockville, MD</publisher-loc>. <publisher-name>Agency for Healthcare Research and Quality</publisher-name>. <month>April</month> <year>2012</year>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.effectivehealthcare.ahrq.gov/reports/final.cfm">www.effectivehealthcare.ahrq.gov/reports/final.cfm</ext-link></citation>
</ref>
<ref id="bibr13-0272989X13481110">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berry</surname><given-names>SM</given-names></name>
<name><surname>Ishak</surname><given-names>KJ</given-names></name>
<name><surname>Luce</surname><given-names>BR</given-names></name>
<name><surname>Berry</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Bayesian meta-analyses for comparative effectiveness and informing coverage decisions</article-title>. <source>Med Care</source>. <year>2010</year>;<volume>48</volume>(<issue>Suppl 6</issue>):<fpage>S137</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X13481110">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Regan</surname><given-names>C</given-names></name>
<name><surname>Ghement</surname><given-names>I</given-names></name>
<name><surname>Eyawo</surname><given-names>O</given-names></name>
<name><surname>Guyatt</surname><given-names>GH</given-names></name>
<name><surname>Mills</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison</article-title>. <source>Trials</source>. <year>2009</year>;<volume>10</volume>:<fpage>86</fpage>.</citation>
</ref>
<ref id="bibr15-0272989X13481110">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>A</given-names></name>
</person-group>. <article-title>Assessing evidence inconsistency in mixed treatment comparisons</article-title>. <source>J Am Stat Assoc</source>. <year>2006</year>;<volume>101</volume>:<fpage>447</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X13481110">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haylen</surname><given-names>BT</given-names></name>
<name><surname>de Ridder</surname><given-names>D</given-names></name>
<name><surname>Freeman</surname><given-names>RM</given-names></name>
<etal/>
</person-group>. <article-title>An International Urogynecological Association (IUGA) International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction</article-title>. <source>Neurourol Urodyn</source>. <year>2010</year>;<volume>29</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X13481110">
<label>17.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Abrams</surname><given-names>P</given-names></name>
</person-group>. <conf-name>Incontinence: 4th International Consultation on Incontinence, Paris</conf-name>, <conf-date>July 5–8, 2008</conf-date>. <conf-loc>Paris, France: Health Publications Ltd</conf-loc>; <year>2009</year>. Committee 12. Adult Conservative Management.</citation>
</ref>
<ref id="bibr18-0272989X13481110">
<label>18.</label>
<citation citation-type="gov">
<collab>US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health</collab>. <article-title>Draft Guidance for Industry and FDA Staff—Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence</article-title>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Food and Drug Administration</publisher-name>; <year>2008</year>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm">http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm</ext-link></citation>
</ref>
<ref id="bibr19-0272989X13481110">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coyne</surname><given-names>KS</given-names></name>
<name><surname>Sexton</surname><given-names>CC</given-names></name>
<name><surname>Kopp</surname><given-names>ZS</given-names></name>
<name><surname>Ebel-Bitoun</surname><given-names>C</given-names></name>
<name><surname>Milsom</surname><given-names>I</given-names></name>
<name><surname>Chapple</surname><given-names>C</given-names></name>
</person-group>. <article-title>The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS</article-title>. <source>BJU Int</source>. <year>2011</year>;<volume>108</volume>(<issue>9</issue>):<fpage>1459</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X13481110">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Barbui</surname><given-names>C</given-names></name>
<name><surname>Salanti</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>378</volume>(<issue>9799</issue>):<fpage>1306</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X13481110">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>A</given-names></name>
</person-group>. <article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title>. <source>Stat Med</source>. <year>2004</year>;<volume>23</volume>(<issue>20</issue>):<fpage>3105</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X13481110">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DerSimonian</surname><given-names>R</given-names></name>
<name><surname>Laird</surname><given-names>N</given-names></name>
</person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X13481110">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>TC</given-names></name>
<name><surname>Speigelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Thomas</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Bayesian approaches to random-effects meta-analysis: a comparative study</article-title>. <source>Stat Med</source>. <year>1995</year>;<volume>14</volume>:<fpage>2685</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X13481110">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gelman</surname><given-names>A</given-names></name>
</person-group>. <article-title>Prior distribution for variance parameters in hierarchical models</article-title>. <source>Bayesian Anal</source>. <year>2006</year>;<volume>1</volume>(<issue>3</issue>):<fpage>515</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X13481110">
<label>25.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Dias</surname><given-names>S</given-names></name>
<name><surname>Welton</surname><given-names>NJ</given-names></name>
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Caldwell</surname><given-names>DM</given-names></name>
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials</article-title>. <year>2011</year>. <access-date>Last updated April 2012</access-date>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.nicedsu.org.uk">http://www.nicedsu.org.uk</ext-link></citation>
</ref>
<ref id="bibr26-0272989X13481110">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Best</surname><given-names>NG</given-names></name>
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>van der Linde</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bayesian measures of model complexity and fit</article-title>. <source>J R Stat Soc B</source>. <year>2002</year>;<volume>64</volume>(<issue>4</issue>):<fpage>583</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X13481110">
<label>27.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>Louis</surname><given-names>TA</given-names></name>
</person-group>. <source>Bayesian Methods for Data Analysis</source>. <edition>3rd ed.</edition> <publisher-loc>London</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr28-0272989X13481110">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>B</given-names></name>
<name><surname>Roger</surname><given-names>J</given-names></name>
<name><surname>Lane</surname><given-names>PW</given-names></name>
<etal/>
</person-group>. <article-title>Statistical approaches for conducting network meta-analysis in drug development</article-title>. <source>Pharm Stat</source>. <year>2011</year>;<volume>10</volume>(<issue>6</issue>):<fpage>523</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X13481110">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>IR</given-names></name>
</person-group>. <article-title>Multivariate random-effects meta-regression: updates to mvmeta</article-title>. <source>Stata J</source>. <year>2011</year>;<volume>11</volume>(<issue>2</issue>):<fpage>255</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr30-0272989X13481110">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lunn</surname><given-names>D</given-names></name>
<name><surname>Thomas</surname><given-names>A</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
</person-group>. <article-title>WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility</article-title>. <source>Stat Comput</source>. <year>2000</year>;<volume>10</volume>:<fpage>325</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X13481110">
<label>31.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>Hong</surname><given-names>H</given-names></name>
<name><surname>Shamliyan</surname><given-names>TA</given-names></name>
<name><surname>Sainfort</surname><given-names>F</given-names></name>
<name><surname>Kane</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Case Study Comparing Bayesian and Frequentist Approaches for Multiple Treatment Comparisons</article-title>. (Prepared by the MinnesotaEvidence-based Practice Center under Contract No. 290-2007- 10064-I2.) AHRQ Publication No. 12-EHC103-EF. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Agency for Healthcare Research and Quality</publisher-name>; <year>2012</year>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.effectivehealthcare.gov/reports/final.cfm">www.effectivehealthcare.gov/reports/final.cfm</ext-link></citation>
</ref>
<ref id="bibr32-0272989X13481110">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salanti</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Ioannidis</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial</article-title>. <source>J Clin Epidemiol</source>. <year>2011</year>;<volume>64</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr33-0272989X13481110">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sweeting</surname><given-names>MJ</given-names></name>
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
</person-group>. <article-title>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</article-title>. <source>Stat Med</source>. <year>2004</year>;<volume>23</volume>(<issue>9</issue>):<fpage>1351</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr34-0272989X13481110">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riley</surname><given-names>RD</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
<name><surname>Staessen</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Meta-analysis of continuous outcomes combining individual patient data and aggregate data</article-title>. <source>Stat Med</source>. <year>2008</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1870</fpage>–<lpage>1893</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>